Josette Eris - Concepedia

Author

Josette Eris

Royal Prince Alfred Hospital

Also Known As

J Eris, J M Eris, J M. Eris, J. Eris, J. M. Eris, J.M. Eris, JOSETTE ERIS, JOSETTE M ERIS, Josette ERIS, Josette Eris

102

Publications

4.8K

Citations

H-Index

Concepts

All Affiliations

Royal Prince Alfred Hospital The University of Sydney Novartis (Switzerland)Hospital do Rim e Hipertensão Charité - Universitätsmedizin Berlin

About

Josette Eris is an author at Royal Prince Alfred Hospital specializing in medicine, kidney transplant, and nephrology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	20	2.4K
2	Allergy	3	3	285
3	Public Health	2	2	109
4	Health Sciences	1	1	70
5	Biostatistics	1	1	20

Josette Eris

Publications

4.5K

Citations

H-Index

Page 1

	Year	Citations
TLR4 activation mediates kidney ischemia/reperfusion injury Huiling Wu, Gang Chen, Kate Wyburn, Journal of Clinical Investigation InflammationCytokineIschemia/reperfusion InjuryInnate Immune SystemImmunology	2007	822
Sirolimus Therapy after Early Cyclosporine Withdrawal Reduces the Risk for Cancer in Adult Renal Transplantation Josep M. Campistol, Josette Eris, Rainer Oberbauer, Journal of the American Society of Nephrology Transplantation MedicineDermatologySrl TherapyRelative Risk Srl-stSrl Troughs	2006	472
SIROLIMUS ALLOWS EARLY CYCLOSPORINE WITHDRAWAL IN RENAL TRANSPLANTATION RESULTING IN IMPROVED RENAL FUNCTION AND LOWER BLOOD PRESSURE1,2,10 Robert W. Johnson, Henri Kreis, Rainer Oberbauer, Transplantation	2001	435
Real‐time reverse transcriptase–polymerase chain reaction (RT–PCR) for measurement of cytokine and growth factor mRNA expression with fluorogenic probes or SYBR Green I Jian Yin, Nicholas Shackel, Amany Zekry, Immunology and Cell Biology	2001	299
Everolimus with Optimized Cyclosporine Dosing in Renal Transplant Recipients: 6-Month Safety and Efficacy Results of Two Randomized Studies Hélio Tedesco‐Silva, Josette Eris, Julio Pascual, American Journal of Transplantation	2004	256
Long-Term Cancer Risk of Immunosuppressive Regimens after Kidney Transplantation Martin Gallagher, Patrick J. Kelly, Meg Jardine, Journal of the American Society of Nephrology Cancer ManagementFunctioning TransplantDermatologyCancer OutcomesImmunotherapy	2010	213
FTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1-Year, Randomized Controlled Trial in Europe and Australasia Maurizio Salvadori, Klemens Budde, B Charpentier, American Journal of Transplantation Bpar IncidenceTransplantation MedicineImmunologyRenal TransplantationImmunotherapy	2006	147
Immunoglobulin M and D antigen receptors are both capable of mediating B lymphocyte activation, deletion, or anergy after interaction with specific antigen. Robert Brink, Christopher C. Goodnow, J. Crosbie, The Journal of Experimental Medicine Immune ActivationConventional B CellsLymphocyte DevelopmentImmunologyImmunodominance	1992	145
Anergic self-reactive B cells present self antigen and respond normally to CD40-dependent T-cell signals but are defective in antigen-receptor-mediated functions. Josette Eris, Antony Basten, Robert Brink, Proceedings of the National Academy of Sciences Adaptive Immune SystemT-regulatory CellImmunologyImmunodominanceImmunologic Mechanism	1994	110
12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients Hélio Tedesco‐Silva, Julio Pascual, Josette Eris, Transplant International	2006	103

Page 1